Skip to search formSkip to main contentSkip to account menu

ADL5859

Known as: ADL 5859, ADL-5859 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development
  • V. SpahnC. Stein
  • Expert Opinion on Investigational Drugs
  • 2017
  • Corpus ID: 22258505
ABSTRACT Introduction: Opioids are widely used to treat severe pain. Most clinically used opioids activate µ-opioid receptors… 
2016
2016
Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test.
2015
2015
Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures
2014
2014
In vivo properties of KNT‐127, a novel δ opioid receptor agonist: receptor internalization, antihyperalgesia and antidepressant effects in mice
Activation of δ opioid (DOP) receptors regulates pain and emotional responses, and also displays ligand‐biased agonism. KNT‐127… 
2013
2013
Novel Screening Assay for the Selective Detection of G-Protein-Coupled Receptor Heteromer Signaling
Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to… 
Highly Cited
2012
Highly Cited
2012
δ-Opioid Mechanisms for ADL5747 and ADL5859 Effects in Mice: Analgesia, Locomotion, and Receptor Internalization
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4… 
2012
2012
Delta opioid mechanisms for ADL 5747 and ADL 5859 effects in mice : analgesia , locomotion and receptor internalization
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de… 
Highly Cited
2009
Highly Cited
2009
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).
Selective, nonpeptidic delta opioid receptor agonists have been the subject of great interest as potential novel analgesic agents… 
Highly Cited
2008
Highly Cited
2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Selective delta opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)